Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 540

1.

Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.

Olive C, Ho MF, Dyer J, Lincoln D, Barozzi N, Toth I, Good MF.

J Infect Dis. 2006 Jun 15;193(12):1666-76. Epub 2006 May 10.

PMID:
16703510
2.

Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.

Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF.

J Infect Dis. 2006 Aug 1;194(3):316-24. Epub 2006 Jun 30.

PMID:
16826479
3.

Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.

Olive C, Hsien K, Horváth A, Clair T, Yarwood P, Toth I, Good MF.

Vaccine. 2005 Mar 18;23(17-18):2298-303.

PMID:
15755615
4.

Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.

Olive C, Schulze K, Sun HK, Ebensen T, Horváth A, Toth I, Guzman CA.

Vaccine. 2007 Feb 26;25(10):1789-97. Epub 2006 Nov 30.

PMID:
17229503
6.

Lipid core peptide technology and group A streptococcal vaccine delivery.

Olive C, Batzloff MR, Toth I.

Expert Rev Vaccines. 2004 Feb;3(1):43-58. Review.

PMID:
14761243
7.

A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Olive C, Batzloff MR, Horváth A, Wong A, Clair T, Yarwood P, Toth I, Good MF.

Infect Immun. 2002 May;70(5):2734-8.

8.

Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.

Olive C, Batzloff M, Horváth A, Clair T, Yarwood P, Toth I, Good MF.

Infect Immun. 2003 May;71(5):2373-83.

10.
11.
12.

Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice.

Dunn LA, McMillan DJ, Batzloff M, Zeng W, Jackson DC, Upcroft JA, Upcroft P, Olive C.

Vaccine. 2002 Jun 21;20(21-22):2635-40.

PMID:
12034087
13.

Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.

Horváth A, Olive C, Karpati L, Sun HK, Good M, Toth I.

J Med Chem. 2004 Jul 29;47(16):4100-4.

PMID:
15267249
16.

M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.

Vohra H, Dey N, Gupta S, Sharma AK, Kumar R, McMillan D, Good MF.

Res Microbiol. 2005 May;156(4):575-82. Epub 2005 Feb 19.

PMID:
15862457
17.

Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.

Simerska P, Abdel-Aal AB, Fujita Y, Moyle PM, McGeary RP, Batzloff MR, Olive C, Good MF, Toth I.

J Med Chem. 2008 Mar 13;51(5):1447-52. doi: 10.1021/jm701410p. Epub 2008 Feb 16.

PMID:
18278857
18.

Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.

Georgousakis MM, Hofmann A, Batzloff MR, McMillan DJ, Sriprakash KS.

Vaccine. 2009 Nov 12;27(48):6799-806. doi: 10.1016/j.vaccine.2009.08.049. Epub 2009 Sep 1.

PMID:
19729086
19.

Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.

Chuan YP, Wibowo N, Connors NK, Wu Y, Hughes FK, Batzloff MR, Lua LH, Middelberg AP.

Biotechnol Bioeng. 2014 Jun;111(6):1062-70. doi: 10.1002/bit.25172. Epub 2013 Dec 28.

PMID:
24338691
20.

Supplemental Content

Support Center